JP2007522237A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007522237A5 JP2007522237A5 JP2006553282A JP2006553282A JP2007522237A5 JP 2007522237 A5 JP2007522237 A5 JP 2007522237A5 JP 2006553282 A JP2006553282 A JP 2006553282A JP 2006553282 A JP2006553282 A JP 2006553282A JP 2007522237 A5 JP2007522237 A5 JP 2007522237A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- effective amount
- therapeutically effective
- interferon
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 7
- 208000036142 Viral infection Diseases 0.000 claims 5
- 230000029812 viral genome replication Effects 0.000 claims 5
- 230000009385 viral infection Effects 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- IWUCXVSUMQZMFG-RGDLXGNYSA-N 1-[(2s,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 IWUCXVSUMQZMFG-RGDLXGNYSA-N 0.000 claims 3
- 102000006992 Interferon-alpha Human genes 0.000 claims 3
- 108010047761 Interferon-alpha Proteins 0.000 claims 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229960000329 ribavirin Drugs 0.000 claims 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229940121740 Inosine monophosphate dehydrogenase inhibitor Drugs 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 101710144111 Non-structural protein 3 Proteins 0.000 claims 1
- 229940122055 Serine protease inhibitor Drugs 0.000 claims 1
- 101710102218 Serine protease inhibitor Proteins 0.000 claims 1
- 108010078233 Thymalfasin Proteins 0.000 claims 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000002348 inosinate dehydrogenase inhibitor Substances 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 239000003001 serine protease inhibitor Substances 0.000 claims 1
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims 1
- 229950006081 taribavirin Drugs 0.000 claims 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims 1
- 229960004231 thymalfasin Drugs 0.000 claims 1
- UUWJNBOCAPUTBK-UHFFFAOYSA-N C[n]1c(N=C(N)NC2=O)c2nc1 Chemical compound C[n]1c(N=C(N)NC2=O)c2nc1 UUWJNBOCAPUTBK-UHFFFAOYSA-N 0.000 description 1
- 0 C[n]1c(nc(N)nc2*)c2nc1 Chemical compound C[n]1c(nc(N)nc2*)c2nc1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54474304P | 2004-02-13 | 2004-02-13 | |
| US10/903,215 US20050182252A1 (en) | 2004-02-13 | 2004-07-29 | Novel 2'-C-methyl nucleoside derivatives |
| PCT/US2005/004447 WO2005084192A2 (en) | 2004-02-13 | 2005-02-14 | Novel 2’-c-methyl nucleoside derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007522237A JP2007522237A (ja) | 2007-08-09 |
| JP2007522237A5 true JP2007522237A5 (enExample) | 2008-08-21 |
Family
ID=34841195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006553282A Pending JP2007522237A (ja) | 2004-02-13 | 2005-02-14 | 新規2’−c−メチルヌクレオシド誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US20050182252A1 (enExample) |
| EP (1) | EP1720556A4 (enExample) |
| JP (1) | JP2007522237A (enExample) |
| BR (1) | BRPI0507675A (enExample) |
| WO (1) | WO2005084192A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7200970B2 (en) * | 2004-02-09 | 2007-04-10 | Trim-Tex, Inc. | Combination comprising vertical wall, horizontal ceiling, and crown molding member having planar portion, intermediate portion, and mounting flange |
| US20050182252A1 (en) * | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
| US20080280842A1 (en) * | 2004-10-21 | 2008-11-13 | Merck & Co., Inc. | Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection |
| CA2602533A1 (en) | 2005-03-29 | 2006-10-05 | Biocryst Pharmaceuticals, Inc. | Use of c-nucleoside analogs for treatment of hepatitis c related viral infections |
| AU2007338899A1 (en) * | 2006-12-20 | 2008-07-03 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| EP2124555B1 (en) * | 2007-01-05 | 2015-07-08 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| SG177974A1 (en) | 2007-01-12 | 2012-02-28 | Biocryst Pharm Inc | Antiviral nucleoside analogs |
| TW200942243A (en) | 2008-03-05 | 2009-10-16 | Biocryst Pharm Inc | Antiviral therapeutic agents |
| WO2010036407A2 (en) | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
| WO2010014134A1 (en) * | 2008-07-02 | 2010-02-04 | Idenix Pharamaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US8680071B2 (en) | 2010-04-01 | 2014-03-25 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| EP2691409B1 (en) | 2011-03-31 | 2018-02-21 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US20140356325A1 (en) * | 2012-01-12 | 2014-12-04 | Ligand Pharmaceuticals Incorporated | Novel 2'-c-methyl nucleoside derivative compounds |
| US9326991B2 (en) | 2012-09-14 | 2016-05-03 | Ligand Pharmaceuticals, Inc. | Nucleotide prodrug compounds and use |
| US9676809B2 (en) | 2013-11-22 | 2017-06-13 | Ligand Pharmaceuticals Incorporated | Derivatives of uridine 5′-cyclophosphate useful to treat hepatitis C viral infections |
| AU2015217221A1 (en) | 2014-02-13 | 2016-08-11 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
| JP2017520545A (ja) | 2014-07-02 | 2017-07-27 | リガンド・ファーマシューティカルズ・インコーポレイテッド | プロドラッグ化合物およびそれらの使用 |
| GEAP202215528A (en) | 2015-03-06 | 2022-11-10 | Atea Pharmaceuticals Inc | B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT |
| BR112019004297A2 (pt) | 2016-09-07 | 2019-05-28 | Atea Pharmaceuticals Inc | método, uso de uma quantidade eficaz de um composto, composto, e, composição farmacêutica. |
| CN106518942B (zh) * | 2016-10-24 | 2019-04-19 | 银杏树药业(苏州)有限公司 | 用于治疗hcv感染的新型环磷酯 |
| SG11201906163TA (en) | 2017-02-01 | 2019-08-27 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus |
| US11040947B2 (en) | 2017-03-22 | 2021-06-22 | The Research Foundation For The State University Of New York | Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors |
| CA3087932A1 (en) | 2018-01-09 | 2019-07-18 | Ligand Pharmaceuticals, Inc. | Acetal compounds and therapeutic uses thereof |
| EP3773753A4 (en) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| JP2024525164A (ja) | 2021-06-17 | 2024-07-10 | アテア ファーマシューティカルズ, インコーポレイテッド | 有利な抗hcv併用療法 |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL99688C (enExample) * | 1956-12-20 | |||
| US5763596A (en) * | 1989-09-15 | 1998-06-09 | Metabasis Therapeutics, Inc. | C-4' modified adenosine kinase inhibitors |
| AU673055B2 (en) * | 1993-02-03 | 1996-10-24 | Gensia, Inc. | Adenosine kinase inhibitors comprising lyxofuranosyl derivatives |
| US5514798A (en) * | 1993-06-02 | 1996-05-07 | Gilead Sciences, Inc. | Method and cyclic carbonates for nucleotide analogues |
| CA2246162C (en) | 1996-01-23 | 2000-04-04 | Icn Pharmaceuticals, Inc. | Modulation of th1/th2 cytokine expression by ribavirin.rtm. and ribavirin.rtm. analogs in activated t-lymphocytes |
| US6128582A (en) | 1996-04-30 | 2000-10-03 | Vertex Pharmaceuticals Incorporated | Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them |
| HUP0001186A3 (en) | 1996-10-16 | 2002-04-29 | Icn Pharmaceuticals Inc Costa | Purine l-nucleosides,analogs and pharmaceutical compositions thereof |
| CN1268140A (zh) | 1996-10-16 | 2000-09-27 | Icn药品公司 | 单环l-核苷、类似物及其应用 |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| HUP9904040A3 (en) | 1996-11-19 | 2000-09-28 | Icn Pharmaceuticals Inc Costa | Multivalent salts of pyridostigmine and related compounds |
| CZ227199A3 (cs) | 1996-12-27 | 1999-12-15 | Icn, Pharmaceuticals, Inc. | Aptamer |
| CN1253504A (zh) | 1997-01-17 | 2000-05-17 | Icn药品公司 | 细胞因子相关的疾病治疗法 |
| SE9700792L (sv) | 1997-03-06 | 1998-02-23 | Carlo Castro | Ryggsmörjare för insmörjning av hudkräm på en människokropp |
| GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
| YU67099A (sh) | 1997-06-30 | 2002-06-19 | Icn Pharmaceuticals Inc. | Postupak za dobijanje tiazofurina i drugih c-nukleozida |
| IL121413A (en) | 1997-07-28 | 2000-10-31 | Green Cloud Ltd | Method for reducing the accumulation of precipitates and impurities on ultrasonic transducers |
| DK1003775T3 (da) | 1997-08-11 | 2005-05-30 | Boehringer Ingelheim Ca Ltd | Hepatitis C-inhibitorpeptider |
| WO1999007734A2 (en) | 1997-08-11 | 1999-02-18 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
| WO1999036074A1 (en) | 1998-01-15 | 1999-07-22 | Icn Pharmaceuticals, Inc. | Use of 8-cl-camp in prevention of restenosis of arterial walls |
| AU2787199A (en) | 1998-02-25 | 1999-09-15 | Emory University | 2'-fluoronucleosides |
| US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| JP4741725B2 (ja) * | 1998-03-06 | 2011-08-10 | メタベイシス・セラピューティクス・インコーポレーテッド | リン含有化合物のための新規なプロドラッグ |
| GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
| EP1066247B1 (en) | 1998-03-31 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| WO1999060855A1 (en) | 1998-05-26 | 1999-12-02 | Icn Pharmaceuticals, Inc. | Novel nucleosides having bicyclic sugar moiety |
| GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6045638A (en) | 1998-10-09 | 2000-04-04 | Atlantic Research Corporation | Monopropellant and propellant compositions including mono and polyaminoguanidine dinitrate |
| AU764479B2 (en) | 1998-10-29 | 2003-08-21 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
| PL364699A1 (en) | 1999-01-29 | 2004-12-13 | Icn Pharmaceuticals, Inc. | Modulation of immune response by ribavirin |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| DK1196414T3 (da) | 1999-06-25 | 2003-11-24 | Vertex Pharma | Prolægemiddel af carbamathæmmer for IMPDH |
| KR20020092904A (ko) | 1999-08-27 | 2002-12-12 | 아이씨엔 파마슈티컬스, 인코포레이티드 | 피롤로[2,3-d]피리미딘 누클레오사이드 유사체 |
| US6752981B1 (en) * | 1999-09-08 | 2004-06-22 | Metabasis Therapeutics, Inc. | Prodrugs for liver specific drug delivery |
| US6518253B1 (en) | 1999-11-19 | 2003-02-11 | Robert Tam | Treatment of viral infections using the L-isomer of ribavirin |
| WO2001045642A2 (en) | 1999-12-13 | 2001-06-28 | Icn Pharmaceuticals, Inc. | Pulmonary delivery of ribavirin or levovirin™ for systemic and quasi-systemic treatment of disease |
| SK8612002A3 (en) | 1999-12-23 | 2003-03-04 | Ribapharm Inc | Compositions and methods for L-nucleosides, L-nucleotides, and their analogs |
| CA2363274A1 (en) | 1999-12-27 | 2001-07-05 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs for hepatitis c |
| US6455508B1 (en) | 2000-02-15 | 2002-09-24 | Kanda S. Ramasamy | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
| US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
| WO2001077091A2 (en) | 2000-04-05 | 2001-10-18 | Tularik Inc. | Ns5b hcv polymerase inhibitors |
| ES2319732T3 (es) | 2000-04-13 | 2009-05-12 | Pharmasset, Inc. | Derivados de nucleosido 3'- o 2'-hidroximetilo sustituido para el tratamiento de infecciones virales. |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| JP5230052B2 (ja) * | 2000-05-26 | 2013-07-10 | イデニクス(ケイマン)リミテツド | フラビウイルスおよびペスチウイルス治療のための方法および組成物 |
| UA72612C2 (en) | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
| CA2416748A1 (en) | 2000-08-22 | 2002-02-28 | Ribapharm Inc. | Improved specificity in treatment of diseases |
| KR20030040416A (ko) | 2000-08-22 | 2003-05-22 | 리버팜 인크. | 간세포에 약물을 전달하는 방법 및 플라비비리대 감염을치료하는 방법 |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| US6809101B2 (en) | 2000-09-01 | 2004-10-26 | Shionogi & Co., Ltd. | Compounds having anti-hepatitis C virus effect |
| ATE491459T1 (de) | 2000-10-18 | 2011-01-15 | Pharmasset Inc | Modifizierte nukleoside zur behandlung von virusinfektionen und abnormaler zellulärer proliferation |
| CN1301994C (zh) | 2000-12-12 | 2007-02-28 | 先灵公司 | 作为c型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的二芳基肽 |
| AU2002230763A1 (en) | 2000-12-13 | 2008-01-03 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
| WO2002048165A2 (en) | 2000-12-15 | 2002-06-20 | Pharmasset Ltd. | Antiviral agents for treatment of flaviviridae infections |
| EP1346724A4 (en) | 2000-12-26 | 2004-11-17 | Mitsubishi Pharma Corp | AGENT FOR TREATING HEPATITIS C |
| DZ3487A1 (fr) | 2001-01-22 | 2002-07-25 | Merck Sharp & Dohme | Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant |
| GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| WO2002102307A2 (en) | 2001-06-15 | 2002-12-27 | Ribapharm | Nucleoside vaccine adjuvants |
| GB0119369D0 (en) | 2001-08-08 | 2001-10-03 | Bookham Technology Plc | Optic system |
| GB2378524A (en) | 2001-08-08 | 2003-02-12 | Bookham Technology Plc | Intergrated optic device |
| US20040006002A1 (en) | 2001-09-28 | 2004-01-08 | Jean-Pierre Sommadossi | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
| WO2003026589A2 (en) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
| US20030072451A1 (en) | 2001-10-16 | 2003-04-17 | Pimentel Roberto J. | Method and apparatus for securely transferring wireless data |
| WO2003034709A1 (fr) | 2001-10-17 | 2003-04-24 | Naltec Inc. | Procede de decompression et dispositif de traitement de donnees |
| WO2003037908A1 (en) | 2001-10-31 | 2003-05-08 | Ribapharm Inc. | Antiviral combination therapy and compositions |
| WO2003051881A1 (en) | 2001-12-17 | 2003-06-26 | Ribapharm Inc. | Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies |
| AU2002353165A1 (en) | 2001-12-17 | 2003-06-30 | Ribapharm Inc. | Deazapurine nucleoside libraries and compounds |
| WO2003051898A1 (en) | 2001-12-17 | 2003-06-26 | Ribapharm Inc. | Unusual nucleoside libraries, compounds, and preferred uses as antiviral and anticancer agents |
| AU2002357876A1 (en) | 2001-12-17 | 2003-06-30 | Ribapharm Inc. | Nucleoside analog libraries and compounds |
| AU2002349905A1 (en) | 2001-12-17 | 2003-06-30 | Ribapharm Inc. | Nucleoside libraries and compounds by mcc combinatorial strategies on solid support |
| AU2002340387A1 (en) | 2001-12-17 | 2003-06-30 | Ribapharm Inc. | Cytidine libraries and compounds synthesized by solid-phase combinatorial strategies |
| AU2002359919A1 (en) | 2001-12-28 | 2003-07-24 | Terumo Kabushiki Kaisha | Syringe |
| WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
| EP1572705A2 (en) * | 2002-01-17 | 2005-09-14 | Ribapharm, Inc. | Sugar modified nucleosides as viral replication inhibitors |
| US7323453B2 (en) * | 2002-02-13 | 2008-01-29 | Merck & Co., Inc. | Methods of inhibiting orthopoxvirus replication with nucleoside compounds |
| US20040063658A1 (en) * | 2002-05-06 | 2004-04-01 | Roberts Christopher Don | Nucleoside derivatives for treating hepatitis C virus infection |
| US7214668B2 (en) * | 2002-05-13 | 2007-05-08 | Metabasis Therapeutics, Inc. | Phosphonic acid based prodrugs of PMEA and its analogues |
| AU2003235501A1 (en) * | 2002-05-13 | 2003-11-11 | Metabasis Therapeutics, Inc. | PMEA and PMPA cyclic producing synthesis |
| EP1572945A2 (en) * | 2002-06-27 | 2005-09-14 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| WO2004003000A2 (en) | 2002-06-28 | 2004-01-08 | Idenix (Cayman) Limited | 1’-, 2'- and 3'- modified nucleoside derivatives for treating flaviviridae infections |
| TW200500375A (en) | 2002-06-28 | 2005-01-01 | Idenix Cayman Ltd | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae |
| AP2005003213A0 (en) * | 2002-06-28 | 2005-03-31 | Univ Cagliari | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections. |
| WO2004007512A2 (en) * | 2002-07-16 | 2004-01-22 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| SG174624A1 (en) | 2002-08-01 | 2011-10-28 | Pharmasset Inc | Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections |
| TW200418498A (en) * | 2002-09-30 | 2004-10-01 | Genelabs Tech Inc | Nucleoside derivatives for treating hepatitis C virus infection |
| BR0315795A (pt) * | 2002-10-31 | 2005-09-13 | Metabasis Therapeutics Inc | Pró-medicamentos de monofosfato de citarabina |
| US7824851B2 (en) | 2002-11-15 | 2010-11-02 | Idenix Pharmaceuticals, Inc. | 2′-branched nucleosides and Flaviviridae mutation |
| TWI294882B (en) * | 2002-12-09 | 2008-03-21 | Hoffmann La Roche | Anhydrous crystalline azido cytosine hemisulfate derivative |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| HRP20130098T1 (hr) | 2003-10-14 | 2013-02-28 | F. Hoffmann - La Roche Ag | MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a |
| US7151089B2 (en) * | 2003-10-27 | 2006-12-19 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
| MXPA06004680A (es) * | 2003-10-27 | 2007-04-17 | Genelabs Tech Inc | Compuestos de nucleosido para el tratamiento de infecciones virales. |
| US20050182252A1 (en) * | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
-
2004
- 2004-07-29 US US10/903,215 patent/US20050182252A1/en not_active Abandoned
-
2005
- 2005-02-14 WO PCT/US2005/004447 patent/WO2005084192A2/en not_active Ceased
- 2005-02-14 BR BRPI0507675-7A patent/BRPI0507675A/pt not_active IP Right Cessation
- 2005-02-14 EP EP05750052A patent/EP1720556A4/en not_active Withdrawn
- 2005-02-14 JP JP2006553282A patent/JP2007522237A/ja active Pending
- 2005-07-29 US US11/572,785 patent/US20090131370A1/en not_active Abandoned
-
2006
- 2006-10-30 US US11/589,363 patent/US7666855B2/en not_active Expired - Lifetime
- 2006-11-06 US US11/593,381 patent/US20070179114A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007522237A5 (enExample) | ||
| JP2008518943A5 (enExample) | ||
| RS20120201A3 (en) | Methods and compositions for hepatitis c virus treatment | |
| JP2010503396A5 (enExample) | ||
| JP2009504157A5 (enExample) | ||
| WO2004014313A3 (en) | Combination pharmaceutical agents as inhibitors of hcv replication | |
| WO2005009418A3 (en) | Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c | |
| WO2007089618A3 (en) | Hepatitis c serine protease inhibitors and uses therefor | |
| RU2011139180A (ru) | Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции | |
| JP2015517528A5 (enExample) | ||
| WO2006130627A3 (en) | Methods for treating hepatitis c | |
| WO2002032414A3 (en) | Ribavirin-pegylated interferon alfa hcv combination therapy | |
| JP2010528013A5 (enExample) | ||
| WO2006000922A3 (en) | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae | |
| HRP20110169T1 (hr) | Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c | |
| JP2013529627A5 (enExample) | ||
| PE20060309A1 (es) | (1r,2s,5s)-n-[(1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.o]hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de l | |
| BRPI0811447A2 (pt) | Compostos, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática e de intensificação da função hepática num indivíduo tendo infecção de vírus da hepatite c. | |
| JP2013507439A5 (enExample) | ||
| JP2008531704A5 (enExample) | ||
| NO20073632L (no) | Behandling av hepatitt C med interferon-beta i en asiatisk populasjon | |
| Bourlière et al. | How to optimize HCV therapy in genotype 1 patients with cirrhosis | |
| WO2009046369A3 (en) | Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c | |
| JP2008508319A5 (enExample) | ||
| HRP20110713T1 (hr) | Postupci liječenja kroničnog virusnog hepatitisa c uz upotrebu ro 113-0830 |